Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: The life study
Open Access
- 17 March 2004
- journal article
- clinical trial
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 43 (6) , 1047-1055
- https://doi.org/10.1016/j.jacc.2003.11.029
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)JAMA, 2002
- Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney DiseaseResults From the AASK TrialJAMA, 2002
- Effects of Losartan on Cardiovascular Morbidity and Mortality in Patients With Isolated Systolic Hypertension and Left Ventricular HypertrophyJAMA, 2002
- The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 DiabetesNew England Journal of Medicine, 2001
- Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and NephropathyNew England Journal of Medicine, 2001
- Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive NephrosclerosisA Randomized Controlled TrialJAMA, 2001
- A Trial of the Beta-Blocker Bucindolol in Patients with Advanced Chronic Heart FailureNew England Journal of Medicine, 2001
- Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trialsJournal of Cardiac Failure, 1999
- Characteristics of 9194 Patients With Left Ventricular HypertrophyHypertension, 1998
- Effect of Single-Drug Therapy on Reduction of Left Ventricular Mass in Mild to Moderate HypertensionCirculation, 1997